tbuckley/cabot-search huggingface dataset:
DDIS-04. MITOXANTRONE POTENTIATES TRAIL-INDUCED APOPTOSIS IN GLIOBLASTOMA MULTIFORME
Authors: Filiz Senbabaoglu, Ahmet Cingoz, Ezgi Kaya, Selena Kazancioglu, Nathan Lack, Ceyda Acilan, Tugba Bagci-Onder
Journal: Neuro-Oncology (2016)

Glioblastoma multiforme (GBM) is the most aggressive and frequent type of primary brain tumor with dismal survival rates. As GBM cells suppress apoptosis and evade death, re-activating dormant apoptotic programs with pro-apoptotic ligands or small molecules might be a promising approach. As such, the tumor-selective killing capacity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential treatment option in GBM. However, many tumor cells are intrinsically resistant and/or acquire resistance to TRAIL. In this study, we conducted an extensive drug-re-profiling screen to identify FDA-approved compounds that can be used clinically as TRAIL-sensitizing agents in GBM. Using selected isogenic GBM cell pairs with differential levels of TRAIL sensitivity, we revealed 26 TRAIL-sensitizing compounds, 13 of which were effective as single agents. One drug, Mitoxantrone, a DNA-damaging agent, did not cause toxicity to non-malignant cells at the doses that synergized with TRAIL on tumor cells. We investigated the downstream changes in apoptosis pathway components upon Mitoxantrone treatment, and observed that Death Receptors (DR4 and DR5) expression was upregulated, and pro-apoptotic and anti-apoptotic gene expression patterns were altered in favor of apoptosis. Together, our results suggest that combination of Mitoxantrone and TRAIL can be a promising therapeutic approach for GBM patients.
More than nine in 10 who take antibiotics abroad return with resistant bacteria
Authors: Susan Mayor
Journal: BMJ (2017)

More than nine in 10 people who take fluoroquinolone antibiotics for traveller’s diarrhoea while abroad return with multi-resistant strains of bacteria, a study following up people returning home to Finland has found.1

Diarrhoea is the most common health problem affecting people who travel to developing countries. Previous research has shown that people who contract diarrhoea while abroad have an increased risk of acquiring antibiotic resistant intestinal bacteria, and the highest risk is in …
A Phase II Trial of Dexamethasone, High-Dose Cytarabine, and Cisplatin (DHAP) in Combination with Rituximab as Salvage Treatment for Patients with Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.
Authors: Ulrich J.M. Mey, John W. Strehl, Katjana S. Orlopp, Dimitri Flieger, J. Birkmann, Anthony Ho, U. Kaiser, Andreas Neubauer, Axel G. Glasmacher, Ingo G.H. Schmidt-Wolf
Journal: Blood (2004)
Therapeutic efficacy of combined PEGylated liposomal doxorubicin and radiofrequency ablation: Comparing single and combined therapy in young and old mice
Authors: Alexander V. Andriyanov, Emma Portnoy, Erez Koren, Semenenko Inesa, Sara Eyal, S. Nahum Goldberg, Yechezkel Barenholz
Journal: Journal of Controlled Release (2017)
Treosulfan + Fludarabine +/− Thymoglobulin - An Effective Low Toxicity Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia.
Authors: Jerzy Holowiecki, Sebastian Giebel, Jerzy Wojnar, Malgorzata Krawczyk-Kulis, Iwona Wylezol, Miroslaw Markiewicz, Tomasz Kruzel, Aleksandra Holowiecka-Goral, Malgorzata Kopera
Journal: Blood (2005)
KEYNOTE-025: Phase 1b study of pembrolizumab (pembro) in Japanese patients (pts) with previously treated PD-L1+ non-small cell lung cancer (NSCLC)
Authors: T. Kato, T. Takahashi, H. Yoshioka, K. Nakagawa, M. Maemondo, K. Yamada, M. Ichiki, H. Tanaka, T. Seto, H. Sakai, K. Kasahara, M. Satouchi, K. Noguchi, T. Shimamoto, M. Nishio
Journal: Annals of Oncology (2016)
Effects of Dexamethasone (DEX) Vs Prednisone (PDN) and High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Asparaginase (C-MTX/ASNase) On Osteonecrosis (ON) Incidence in Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From the Children's Oncology Group (COG) Study AALL0232
Authors: Leonard A. Mattano, Meenakshi Devidas, Naomi Winick, Elizabeth Raetz, Stephen P. Hunger, William L. Carroll, Eric C. Larsen
Journal: Blood (2012)
IMST-10. CD40 SIGNALING DECREASES MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) EXPRESSION AND CORRELATES WITH SURVIVAL IN GLIOBLASTOMA PATIENTS
Authors: Masashi Chonan, Ryuta Saito, Takuhiro Shoji, Ichiyo Shibahara, Masayuki Kanamori, Yukihiko Sonoda, Mika Watanabe, Naoto Ishii, Teiji Tominaga
Journal: Neuro-Oncology (2016)

We previously demonstrated that the high expression levels of CD40/ CD40 ligand (CD40L) correlated with better prognosis in glioblastomas (GBMs). CD40 is a costimulatory molecule and its agonistic antibody, FGK45 has shown to augment antitumor effects of immunotherapy against GL261, glioma cell, and NSCL61, glioma-initiating cell (GIC)-like cell model mice. Studying the mechanism of FGK45 induced anti-tumor effect against glioma models, we identified that the expression of maternal embryonic leucine-zipper kinase (MELK) is down regulated in FGK45 treated mice. MELK is a serine/ threonine kinase involved in cancer cell proliferation and maintenance of stemness. In this study, we evaluated the relationship between CD40 signaling and MELK expression in gliomas. We tested the MELK expression in NSCL61, and Lewis lung carcinoma (LLC) cell model mice treated with FGK45 immunotherapy. Subsequently, we analyzed direct effects of FGK45 against GL261, NSCL61, and LLC in vitro. Then, we assessed the expression of MELK and CD40/ CD40L in GBMs and analyzed the correlation with prognosis. Significant decrease of MELK expressions were found in FGK45 treated tumor model mice. In vitro, FGK45 directly decreased MELK expression in glioma cells. In clinical samples, the higher expression levels of MELK mRNA were associated with poor prognosis in GBMs. Moreover, the expression levels of MELK were inversely correlated with CD40/ CD40L expression. In this study, we demonstrated that CD40 signaling decreases the MELK expression in glioma cells. The high expression of CD40/CD40L was inversely correlated with MELK expression and correlated with better prognosis. Immunotherapy using CD40 agonistic antibody reduces MELK expression and can be promising GIC targeting therapy.
Complex Paterns of Monoclonal Ig Diversification in B-CLL Cells from Different Tissue Compartments.
Authors: Evangelia M. Dimitriadou, Panayiotis Panayiotidis, Vasiliki Karali, Konstantinos Lilakos, Maria K. Angelopoulou, Marina P. Siakantaris, Gerassimos A. Pangalis
Journal: Blood (2005)
Treatment with 177 lu-HH1 Increases CD20 Expression in Non-Hodgkin Lymphoma Cells in Vitro and In Vivo
Authors: Ada H.V. Repetto-Llamazares, Roy Hartvig Larsen, Landsverk Kirsti, Trond Stokke, Bergthora Eiriksdottir, Roman Generalov, Jostein Dahle
Journal: Blood (2015)
Fully automated and sensitive detection of EGFR exon 18, 19, 20 and 21 mutational status in less than 2.5 hours from a single FFPE slice
Authors: M. Reijans, G. Vandercruyssen, I. Keuleers, C. Vandesteene, I. Vandenbroucke, G. Maertens, E. Sablon
Journal: Annals of Oncology (2016)
Allogeneic Stem-Cell Transplantation in Patients with AML and MDS Using Myeloablative Versus Reduced-Intensity Doses of Intravenous Busulfan : The Role of Dose Intensity.
Authors: Avichai Shimoni, Moshe Yeshurun, Izhar Hardan, Abraham Avigdor, Noga Shem-Tov, Isaac Ben-Bassat, Arnon Nagler
Journal: Blood (2004)
Potent Activation of Healthy Donor T-Cells Specific for Mantle Cell Lymphoma Immunoglobulin Derived Peptides by CD40- and TLR7/8-Ligand Matured Dendritic Cells in Vitro
Authors: Liane Bergmann, Matthias Staudinger, Christiane Pott, Ingrid Bolz, Martin Gramatzki, Michael Kneba, Benedikt Gahn
Journal: Blood (2008)
P13.09 Survival and relapse of brain metastases after complete resection of a single brain metastasis without postoperative whole brain radiotherapy - a retrospective study
Authors: J. S. Gjertsen, L. Speet, J. Guirguis, J. E. C. Bromberg, L. G. H. Dewit, H. Thygesen, J. W. Schouten, W. R. Bouwknegt, W. Boogerd, D. Brandsma
Journal: Neuro-Oncology (2016)
MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer
Authors: Valentina R. Minciacchi, Cristiana Spinelli, Mariana Reis-Sobreiro, Lorenzo Cavallini, Sungyong You, Mandana Zandian, Xiaohong Li, Rajeev Mishra, Paola Chiarugi, Rosalyn M. Adam, Edwin M. Posadas, Giuseppe Viglietto, Michael R. Freeman, Emanuele Cocucci, Neil A. Bhowmick, Dolores Di Vizio
Journal: Cancer Research (2017)

Abstract Communication between cancer cells and the tumor microenvironment results in the modulation of complex signaling networks that facilitate tumor progression. Here, we describe a new mechanism of intercellular communication originating from large oncosomes (LO), which are cancer cell–derived, atypically large (1–10 μm) extracellular vesicles (EV). We demonstrate that, in the context of prostate cancer, LO harbor sustained AKT1 kinase activity, nominating them as active signaling platforms. Active AKT1 was detected in circulating EV from the plasma of metastatic prostate cancer patients and was LO specific. LO internalization induced reprogramming of human normal prostate fibroblasts as reflected by high levels of α-SMA, IL6, and MMP9. In turn, LO-reprogrammed normal prostate fibroblasts stimulated endothelial tube formation in vitro and promoted tumor growth in mice. Activation of stromal MYC was critical for this reprogramming and for the sustained cellular responses elicited by LO, both in vitro and in vivo in an AKT1-dependent manner. Inhibition of LO internalization prevented activation of MYC and impaired the tumor-supporting properties of fibroblasts. Overall, our data show that prostate cancer–derived LO powerfully promote establishment of a tumor-supportive environment by inducing a novel reprogramming of the stroma. This mechanism offers potential alternative options for patient treatment. Cancer Res; 77(9); 2306–17. ©2017 AACR.
Photo-Reactive and Non-Natural Amino Acid Epitopes of Human WT1 Enhance Immunogenicity and Allow Kinetic Study of Antigen Processing.
Authors: Kurtis J. Haro, Marta Gomez-Nunez, Tao Dao, Deming Chau, Annie Won, Sindy Escobar-Alvarez, Victoriya Zakhaleva, Tatyana Korontsvit, David Gin, David A. Scheinberg
Journal: Blood (2007)
Dose Escalated CHOP + Etoposide Followed by Repetitive Autologous Stem Cell Transplantation (MegaCHOEP) with or without Rituximab for Primary Treatment of Aggressive NHL.
Authors: Bertram Glass, Marita Kloess, Marcel Reiser, Bernd Metzner, Lorenz H. Truemper, Markus Loeffler, Michael Pfreundschuh, Norbert Schmitz
Journal: Blood (2005)
Dnmt3b Is Dispensable for Hematopoietic Stem Cell Differentiation, but Acts Synergistically with Dnmt3a to Control the Balance Between Self-Renewal and Differentiation
Authors: Allison Mayle, Grant Anthony Challen, Deqiang Sun, Mira Jeong, Min Luo, Rui Chen, Hui Wang, Wei Li, Margaret A. Goodell
Journal: Blood (2012)
Prevalence of Heparin Induced Thrombocytopenia Antibodies During the Period 2004–2011. Relevance to Heparin Contaminants
Authors: Jawed Fareed, Cafer Adiguzel, Debra Hoppensteadt, Walter Jeske, Jeanine M. Walenga, Bruce E Lewis, Harry L. Messmore, Vinod Bansal
Journal: Blood (2011)
A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity
Authors: S. J. Cohen, M. M. Zalupski, M. R. Modiano, P. R. Conkling, Y. Z. Patt, P. Davis, R. T. Dorr, M. L. Boytim, E. M. Hersh
Journal: Journal of Clinical Oncology (2008)

4619 Background: Imexon, inj. (Amplimexon, AMP) is a novel cyanoaziridine (MW: 111) which depletes thiols inducing oxidative stress and apoptosis. Like gemcitabine (Gem), AMP inhibits ribonucleotide reductase and has synergistic cytotoxicity with Gem. This phase I combination study assessed the maximum tolerated dose (MTD) and dose limiting toxicity (DLT). Methods: 96 chemotherapy naïve, advanced pancreatic cancer patients received Gem on days 1, 8, 15 of a 28 day cycle and AMP on days 1–5/15–19 (n=19) or days 1,8, 15 (n=77). Doses of AMP ranged from 200–1,300 mg/m2 with Gem 800 or 1,000 mg/m2. With abdominal cramping as the primary DLT, tissue distribution was tested with 14C AMP in the rat. AMP was evaluated on the isolated guinea pig ileum. Results: Patient characteristics: median age 63 years (range 39–86), ECOG PS 0/1 (%): 38/ 62, metastatic/locally advanced (%): 93/ 7. The MTD was 1,000 mg/m2 of Gem with 875 mg/m2 of AMP days 1, 8, 15 Q 28 days. DLT was grade 3 cramping, abdominal pain and explosive diarrhea, seen in 3/5 patients at 1,300 mg/m2 AMP. At 1,150, 1,000, and 875 mg/m2 AMP, these toxicities were grade 1–2 in 6/9, 7/13, and 5/19 patients, respectively, and ameliorated with atropine. Fatigue (66%), anemia (62%), nausea (55%), vomiting (45%), leukopenia (44%) were other treatment related toxicities (any grade). Of 62 evaluable patients for response, 11 (18%) had partial responses and 31 (50%) stable disease. The median number of cycles was 3 (range 0 -25). In the rat, 14C localized in the pancreas, bowel, and kidneys and excretion was 85% urinary and 15% fecal. AMP at a concentration of 100–1,000 ug/ml contracted the isolated guinea pig ileum similar to acetylcholine and was reversible with atropine. Conclusions: The AMP + gemcitabine combination was well tolerated at full doses of each agent and encouraging antitumor activity was seen. The DLT of the combination is explained by gastrointestinal localization and an atropine reversible cholinergic effect. Phase II studies are planned. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Amplimed Amplimed Amplimed
ATIM-26. PD-1 EXPRESSION BY TUMOR INFILTRATING LYMPHOCYTES IN GLIOBLASTOMA IS A MARKER OF BOTH ACTIVATION AND EXHAUSTION
Authors: Tom Davidson, Melody Hsu, Shaina Sedighim, Diana Moughon, William Yong, Linda Liau, Robert Prins
Journal: Neuro-Oncology (2016)

Multiple studies have identified negative costimulatory factors, such as programmed death-1 (PD-1/PD-L1), as mediators of intratumoral immune responses. Clinical responses to PD-1 pathway inhibition in different malignancies, however, have been varied. In this study we investigated the role of PD-1 expression in glioblastoma (GBM) tumor infiltrating lymphocytes (TIL). Using flow cytometry, we analyzed the PD-1 expression profile of peripheral blood lymphocytes (PBLs) and TIL of 25 GBM patients at surgery in comparison to healthy donors. To further characterize PD-1 expression in T cells, we FACS sorted PD-1+ and PD-1- T cells from GBM tumors and peripheral blood; the expression of 578 genes related to immune activation and function was quantified using RNA hydbridization probe technology. We also performed next generation T cell receptor sequencing of PD-1+ and PD-1- TIL and PBL from malignant glioma patients to study the clonal TCR repertoire. The mean proportion of PD-1+ TIL was significantly elevated in the CD4+ T cell and CD8+ T cell populations when compared to patient PBLs and mean donor PBLs (54.96%±7.25% vs. 26.21%±3.84% [p<0.05] vs. 19.81%±2.86% [p<0.001]) and (52.41%±7.82% vs. 27.82%±3.16% [p<0.05] vs. 17.65%±2.24% [p<0.01%]). PD-1+ TIL had increased expression of immune activating genes (CD25, CD27, CCR5) and inhibitory genes (LAG-3, CTLA-4, TIGIT) in comparison to PD-1- TIL. We found an increase of clonality in PD-1+ TIL compared to PD-1 non-expressing TIL, demonstrating a larger expansion of clonal antigen specific T cells within the PD-1+TIL population. Our data strongly suggests that PD-1 expression by GBM TIL is both a marker of activation and dysfunction. This knowledge should be incorporated into future combinatorial studies with PD-1 monoclonal antibody blockade and other immunotherapeutic strategies.
Self-report of neuropathy from oxaliplatin-based regimens in the treatment of colorectal cancer: With or without bevacizumab.
Authors: X. S. Wang, C. Eng, D. R. Fogelman, M. Malekifar, K. E. Liao, K. Y. Glover, C. S. Cleeland
Journal: Journal of Clinical Oncology (2011)

551 Background: Neuropathy attributed to oxaliplatin-based chemotherapy is a dose limiting factor in the administration of chemotherapy. With premising clinical outomes, bevacizumab (BV) has been added with colorectal cancer (CRC) patients in first line and second- line therapy. Although toxicity been well documented, there is no evidence of the impact of adding BV to oxaliplatin-based chemotherapy on patient's neuropathy development during therapy. Methods: The study enrolled 66 colorectal cancer patients naïve to oxaliplatin or to any microtubule stabilizing agents scheduled for oxaliplatin-based chemotherapy, 29 (44%) of whom also received BV. From first therapy cycle start date, patients rated symptoms weekly during chemotherapy via the M. D. Anderson Symptom Inventory (MDASI), and continued symptom assessment every two weeks for up to 48 weeks. Longitudinal symptom responses were analyzed by mixed-effect modeling which controlled for age, sex, staging, prior diabetes, and total cycles of chemotherapy received. All cases completed at least 2 cycles chemotherapy. Results: A third of the sample was female; 24% were older than 65 years; 59% with stage IV disease. The five most severe symptoms were numbness, fatigue, sleep disturbance, drowsiness, and distress on MDASI symptom items. The severity of patient-reported numbness/tingling, rated on MDASI, increased overtime in following 48 weeks after started therapy (p &lt; 0.0001). Oxaliplatin-based therapy plus BV, compared to no BV in the regimen, resulted a significant lower severity on numbness/tingling during the study period (estimate = -1.1325, p = 0.0005). Older patients reported more numbness/tingling. In contrast, pain severity remained low during the initial cycles of therapy, but significantly increased over time during therapy. Therapy with or without BV did not produce differences in pain development. Conclusions: This prospective study suggests that adding BV to standard oxaliplitin-based therapy for CRC was associated with significantly reduced numbness/tingling development. This observation needs to be confirmed in larger studies. The mechanism(s) by which neuropathy could be attenuated by BV are unknown. No significant financial relationships to disclose.
FOLFOX / Bevacizumab (Beva) +/- Irinotecan in advanced colorectal cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA)
Authors: H.J. Schmoll, B. Garlipp, C. Junghanß, M. Leithauser, A. Vogel, M. Schaefers, U. Kaiser, H.G. Hoeffkes, A. Florschütz, J. Ruessel, S. Kanzler, T. Edelmann, H. Forstbauer, T. Göhler, C. Hannig, B. Hildebrandt, J. Steighardt, F.M. Meinert, F. Cygon, A. Stein
Journal: Annals of Oncology (2016)
Microparticle-Associated Thrombogenic Mechanism Might Compensate Bleeding Tendency in Patients with Myelodysplastic Syndromes.
Authors: Nora V. Butta, Monica Martin Salces, Raquel de Paz, Ihosvany Fernández Bello, Mayte Álvarez Román, Miguel Canales, Victor Jimenez Yuste
Journal: Blood (2012)
Downregulation of DLEU1 Significantly Shortened Survival in a Rituximab-Treated DLEU1 Knockout Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: DLEU1 May Act As a Tumor Suppressor Gene in Pediatric BL
Authors: Sanghoon Lee, Changhong Yin, Janet Ayello, Erin Morris, Carmella van de Ven, Mitchell S. Cairo
Journal: Blood (2015)
NPM-ALK Modulates the p53 Tumour Suppressor Pathway in a JNK and PI 3-Kinase Dependent Manner: MDM-2 Is a Potential Therapeutic Target for the Treatment of ALK-Expressing Malignancies
Authors: Yuxin Cui, Fiona McDuff, Alan Kerby, Hongtau Ye, Suzanne Dawn Turner
Journal: Blood (2008)
Phase 1 Study of Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Japanese Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Authors: Kiyohiko Hatake, Michinori Ogura, Kiyoshi Ando, Kota Tokushige, Chiho Ono, Erik R. Vandendries, Kensei Tobinai
Journal: Blood (2010)
Phase I, safety, tolerability and preliminary efficacy study of tremelimumab (Trem) in combination with gefitinib (Gef) in EGFR-mutant (EGFR-mut) NSCLC (GEFTREM)
Authors: D. Planchard, F. Barlesi, C. Gomez-Roca, J. Mazieres, A. Varga, L. Greillier, N. Chaput, C. Parlavecchio, K. Malekzadeh, M. Ngocamus, S. Zahi, B. Besse, E. Lanoy, J.-C. Soria
Journal: Annals of Oncology (2016)
Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Authors: A.K. Altwairgi, F. Alnajjar, H. Alhussain, E. Alsaeed, A. Balbaid, S. Aldandan, Y. Orz, A. Lary, W. Alghareeb, A. Alsharm
Journal: Annals of Oncology (2019)
Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule?
Authors: Yanina Balabanova, Lena Fiebig, Olga Ignatyeva, Vija Riekstina, Manfred Danilovits, Kaadri Jaama, Edita Davidaviciene, Birute Radiulyte, Christina Marcela Popa, Vladyslav Nikolayevskyy, Francis Drobniewski
Journal: Thorax (2017)

WHO recently recommended the use of a shorter multidrug-resistant TB (MDR-TB) regimen under programmatic conditions. We assessed eligibility for this regimen in a cohort of 737 adult patients with MDR-TB from Latvia, Lithuania, Estonia and Bucharest city recruited in 2007 and 2009. Only 4.2% of the patients were eligible for this regimen. Ethambutol (64%), pyrazinamide resistance (58%) and previous exposure to second-line TB drugs were major reasons for non-eligibility. High-level resistance to isoniazid is expected due to widespread prevalence of katG mutations. In Eastern Europe, the use of the shorter regimen might be an exception rather than a rule.
Family history of colorectal cancer (CRC) in first degree relatives and survival in patients with newly diagnosed synchronous metastatic CRC
Authors: S. Ahmed, S.Y.A. Kazmi, M.E. Emara, T. Asif, R. Alvi, D. Le, N. Iqbal, A. Zaidi, T. Abbas, K. Haider
Journal: Annals of Oncology (2016)
Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)
Authors: P.A. Ascierto, M. Del Vecchio, C. Robert, A. Mackiewicz, V. Chiarion-Sileni, A.M. Arance Fernandez, H. Schmidt, C. Lebbe, L. Bastholt, O. Hamid, P. Rutkowski, C. McNeil, C. Garbe, C. Loquai, B. Dreno, L. Thomas, J.J. Grob, D. Hennicken, A. Qureshi, M. Maio
Journal: Annals of Oncology (2016)
A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Combination with Melphalan and Dexamethasone in Subjects with Newly-Diagnosed Light-Chain (AL)-Amyloidosis.
Authors: Philippe Moreau, Arnaud Jaccard, Lotfi Benboubker, Bruno Royer, Valerie Coiteux, Franck Bridoux, Jean-Luc Harousseau, Catherine Traulle, Bernard Grosbois, Veronique Leblond, May Alakl, Olivier Hermine, Jean-Paul Fermand
Journal: Blood (2008)
Prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancers (TNBC) treated with neoadjuvant chemotherapy (NAC)
Authors: C. Herrero-Vicent, A. Guerrero, J. Gavilá, F. Gozalbo, S. Blanch, A. Hernández, S. Sandiego, A. Calatrava, V. Guillem, A. Ruiz
Journal: Annals of Oncology (2016)
Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
Authors: C. Grommes, I. Gavrilovic, T. Kaley, C. Nolan, A. Omuro, J. Wolfe, E. Pentsova, V. Hatzoglou, I.K. Mellinghoff, L. Deangelis
Journal: Annals of Oncology (2016)